Q1 EPS Estimates for Cytosorbents Lowered by Zacks Research

Cytosorbents Corporation (NASDAQ:CTSO) – Investment analysts at Zacks Research cut their Q1 2026 earnings estimates for shares of Cytosorbents in a report issued on Monday, April 6th. Zacks Research analyst T. Kerr now expects that the medical research company will post earnings per share of ($0.06) for the quarter, down from their prior forecast of ($0.03). The consensus estimate for Cytosorbents’ current full-year earnings is ($0.30) per share. Zacks Research also issued estimates for Cytosorbents’ Q2 2026 earnings at ($0.05) EPS, Q3 2026 earnings at ($0.04) EPS, Q4 2026 earnings at ($0.04) EPS and FY2026 earnings at ($0.19) EPS.

Cytosorbents (NASDAQ:CTSO) last released its earnings results on Wednesday, March 25th. The medical research company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.04). Cytosorbents had a negative return on equity of 131.86% and a negative net margin of 22.12%.The business had revenue of $9.23 million during the quarter, compared to analysts’ expectations of $9.22 million.

CTSO has been the topic of a number of other reports. D. Boral Capital reissued a “buy” rating and issued a $10.00 target price on shares of Cytosorbents in a research note on Thursday, March 26th. Weiss Ratings reissued a “sell (e+)” rating on shares of Cytosorbents in a research note on Friday, January 9th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $5.38.

Cytosorbents Trading Up 1.7%

CTSO opened at $0.62 on Wednesday. The company has a debt-to-equity ratio of 1.61, a current ratio of 2.11 and a quick ratio of 1.71. The company’s 50 day simple moving average is $0.67 and its two-hundred day simple moving average is $0.73. Cytosorbents has a 1-year low of $0.50 and a 1-year high of $1.39. The firm has a market capitalization of $38.88 million, a price-to-earnings ratio of -4.77 and a beta of 1.47.

Institutional Trading of Cytosorbents

Several institutional investors have recently made changes to their positions in CTSO. Goldman Sachs Group Inc. raised its position in shares of Cytosorbents by 149.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock valued at $63,000 after buying an additional 37,519 shares during the period. Avenir Corp raised its position in shares of Cytosorbents by 0.3% during the 2nd quarter. Avenir Corp now owns 5,058,537 shares of the medical research company’s stock valued at $6,475,000 after buying an additional 13,619 shares during the period. Vanguard Group Inc. raised its position in shares of Cytosorbents by 3.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock valued at $2,059,000 after buying an additional 79,535 shares during the period. GSA Capital Partners LLP purchased a new stake in shares of Cytosorbents during the 3rd quarter valued at approximately $105,000. Finally, CM Management LLC raised its position in shares of Cytosorbents by 3.1% during the 3rd quarter. CM Management LLC now owns 1,288,128 shares of the medical research company’s stock valued at $1,203,000 after buying an additional 38,128 shares during the period. Hedge funds and other institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.